Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inebilizumab in Children With Generalized Myasthenia Gravis
NCT06987539Phase 2Recruiting
- Sponsor
- Amgen
- Start
- Jul 2026
- Primary completion
- Mar 2030
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of inebilizumab in myasthenia gravis (MG), sponsored by Amgen. Primary endpoints: Maximum Observed Concentration, Area Under the Concentration-time Curve and 7 more. Started Jul 2026; status: recruiting.
02
Drugs
inebilizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT06987539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06987539.